<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns:ifp="http://www.ifactory.com/press" xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9">
  <ifp:contentType>ARTICLE</ifp:contentType>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/7/2/article-p109.xml</sm:loc>
    <ifp:title>Personalized Medicine and Breast Cancer Care</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/7/2/article-p115.xml</sm:loc>
    <ifp:title>Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/7/2/article-p122.xml</sm:loc>
    <ifp:title>Breast Cancer</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/7/2/article-p193.xml</sm:loc>
    <ifp:title>Indications for Breast MRI in the Patient with Newly Diagnosed Breast Cancer</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/7/2/article-p203.xml</sm:loc>
    <ifp:title>Pharmacogenetics of Tamoxifen: Who Should Undergo CYP2D6 Genetic Testing?</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/7/2/article-p215.xml</sm:loc>
    <ifp:title>Accelerated Partial Breast Irradiation: Where Do We Stand?</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/7/2/article-p226.xml</sm:loc>
    <ifp:title>Geriatric Assessment in Older Patients with Breast Cancer</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
</urlset>
